Posted: 3 month(s) and 28 days(s) ago   |   1 Comment(s)   |   Rating: 1 0
Posted by: In_The_News

AUSTIN, TX--(Marketwire - 11/23/09) - Applied Nanotech Holdings, Inc. (OTC.BB:APNT - News) announced that it has been selected by the U.S. Missile Defense Agency ("MDA") to receive an award of approximately $500,000 for the development of non-contact methods for mitigation of tin whiskers from electronic devices. ANI will partner with the University of Maryland's Center for Advanced Life Cycle Engineering on this project.

Tin whiskers are long hair like structures that commonly grow perpendicular to a metal surface, most commonly on the soldered surfaces and electroplated finishes used in nearly every electronic device made. These whiskers grow over time, causing electrical shorts and arcing that damages the equipment. The damage is most prevalent after several years of use, particularly in the case of lead free solder, which is becoming much more prevalent in the electronics industry.

During this eighteen month Phase II Small Business Innovation Research program, which results from successful completion of a Phase I award, Applied Nanotech will focus on optimizing its patented (pending) process for the mitigation of tin whiskers. Both the MDA and NASA have reported that tin whiskers have been the cause of more than $1 billion in catastrophic damage to satellites, missiles, and other electronic equipment.

Current recognized mitigation techniques add cost and complexity to the manufacturing process and have had mixed success. Our unique ability to perform tin whisker remediation with a pulse of energy, while simultaneously preventing new whiskers from growing, provides a distinct advantage over competitive methods.

"As the world is moving toward lead free solder, the tin whiskers issue will become very problematic, not only for defense and aerospace applications, but for all electronic products," said Dr. Zvi Yaniv, CEO of Applied Nanotech, Inc.

"This improved method of remediation of tin whiskers is a direct outgrowth of our activity in technical inks and pastes," said Doug Baker, CEO of Applied Nanotech Holdings, Inc. "We continue to broaden the applicability of our technology to generate increased revenues."

ABOUT APPLIED NANOTECH HOLDINGS, INC.

Applied Nanotech Holdings, Inc. is a premier research and commercialization organization focused on solving problems at the molecular level. Its team of PhD level scientists and engineers work with companies and other organizations to solve technical impasses and create innovations that will create a competitive advantage. The business model is to license patents and technology to partners that will manufacture and distribute products using the technology. Applied Nanotech has over 250 patents or patents pending. Applied Nanotech's website is www.appliednanotech.net.

SAFE HARBOR STATEMENT

This press release contains forward-looking statements that involve risks and uncertainties concerning our business, products, and financial results. Actual results may differ materially from the results predicted. More information about potential risk factors that could affect our business, products, and financial results are included in our annual report on Form 10-K for the fiscal year ended December 31, 2008, and in reports subsequently filed by us with the Securities and Exchange Commission ("SEC"). All documents are available through the SEC's Electronic Data Gathering Analysis and Retrieval System (EDGAR) at www.sec.gov or from our website listed above. We hereby disclaim any obligation to publicly update the information provided above, including forward-looking statements, to reflect subsequent events or circumstances.

COMPANY CONTACT
Doug Baker
Applied Nanotech Holdings, Inc.
248.391.0612
Email Contact

Add Comment / Rating

Posted: 3 month(s) and 28 days(s) ago   |   0 Comment(s)   |   Rating: 0 0
Posted by: In_The_News

 

VERNON HILLS, IL--(Marketwire - December 22, 2009) - Applied NeuroSolutions, Inc. (OTCBB: APSN) (www.AppliedNeuroSolutions.com), a biotechnology company focused on the development of products for the early diagnosis and treatment of Alzheimer's disease ("AD"), today announced that it has reached agreement with Eli Lilly and Company to increase the scope of its drug discovery collaboration.

In addition to the financial terms from the original collaboration agreement with Lilly announced in 2006, Applied NeuroSolutions will receive an up-front cash payment of $750,000 and may receive up to $25.5 million based on achievement of identified milestones. Royalties would be paid to Applied NeuroSolutions for any AD therapies brought to market that result from this addition to the original collaboration agreement.

"We are expanding our collaboration with Eli Lilly and Company focused on the development of new treatments for patients suffering from Alzheimer's disease," commented Craig S. Taylor, Ph.D., Applied NeuroSolutions' President and CEO. "Lilly continues to see the value in collaborating with Applied NeuroSolutions and our founding scientist, Dr. Peter Davies, a world renowned leader in Alzheimer's disease research. In total, our collaboration has the potential to produce multiple drug candidates, each targeting unique mechanisms."

"APNS has developed valuable reagents for understanding tau biology. We look forward to utilizing these tools, along with Professor Davies' expertise, to accelerate development of therapies that target tau in Alzheimer's disease," said Dr. Michael Hutton, Chief Scientific Officer of the Neurodegeneration Drug Hunting Team at Lilly.

About Applied NeuroSolutions:

Applied NeuroSolutions, Inc. (OTCBB: APSN) is developing diagnostics and therapeutics to detect and treat Alzheimer's disease (AD) building on discoveries originating from the Albert Einstein College of Medicine. Applied NeuroSolutions is in a collaboration with Eli Lilly and Company to develop novel therapeutic compounds to treat the progression of AD. For its diagnostic pipeline, Applied NeuroSolutions is focused on both serum and cerebrospinal fluid (CSF) tests to detect AD at a very early stage. The CSF based P-Tau 231 test now being offered for use in clinical trials can effectively differentiate AD patients from those with other neurological diseases that have similar symptoms. There is currently no FDA approved diagnostic test to detect AD. Alzheimer's disease currently afflicts over five million Americans, and the world market for AD therapy is currently estimated to be nearly 35 million patients. For more information, visit www.AppliedNeuroSolutions.com

This press release contains forward-looking statements about Applied NeuroSolutions. The company wishes to caution the readers of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, the risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, potential competitive offerings, and access to capital. For further information, please visit the company's website at www.AppliedNeuroSolutions.com, and review the company's filings with the Securities and Exchange Commission.

Add Comment / Rating

Posted: 4 month(s) and 2 days(s) ago   |   0 Comment(s)   |   Rating: 0 0
Posted by: In_The_News

"Using our proprietary software Enterprise Circuit Manager (ECM) and our Telco expertise we will deliver a comprehensive cleansed report of TelePacific's telecom circuit lifecycle identifying increased savings in their circuit spend. We usually reduce costs by up to 15-20%," says Steve Fiveash, IETS Head of US operations. "The three year contract means that the cost reduction process will be ongoing. We will be able to make recommendations for fine tuning and optimizing TelePacific's procurement process, provide automated circuit lifecycle management and identify areas for process improvements."

"Our network is one of our largest areas of spend and working with IETS gives us an opportunity to significantly reduce our cost base while continuing to provide high levels of service to our customers," said Craig Maloof, Director, Network Planning and Project Management at TelePacific.

IE Telco Solutions Ltd (IETS), a wholly owned subsidiary of NaeroDynamics, Inc., specializes in managing and reducing telecoms circuit costs for Telcos and large enterprise. The Company offers a powerful combination of highly skilled and experienced telecoms professionals combined with a unique software application Enterprise Circuit Manager (ECM). ECM ensures full circuit lifecycle inventory control, significant data quality improvements, supplier invoice reconciliation, network optimization, and proven cost reduction. www.ietelcosolutions.com

TelePacific is a facility based Competitive Local Exchange Carrier headquartered in Los Angeles. In business since 1998, the Company provides services on TelePacific owned switches and network infrastructure, including local and long distance voice, dedicated Internet access, private networking, and data transport services as well as bundled voice and Internet solutions. www.telepacific.com

Forward-Looking Statements:
Certain information discussed in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the federal securities laws. Although the company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions at the time made, it can give no assurance that its expectations will be achieved. Readers are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are inherently subject to unpredictable and unanticipated risks, trends and uncertainties such as the company's inability to accurately forecast its operating results; the company's potential inability to achieve profitability or generate positive cash flow; the availability of financing; and other risks associated with the company's business. For further information on factors which could impact the company and the statements contained herein, reference should be made to the company's filings with the Securities and Exchange Commission, including annual reports on Form 10-KSB, quarterly reports on Form 10-QSB and current reports on Form 8-K. The company assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events.

Steve Fiveash
Head of US Business
+1 404-543-4731
 Email Contact
Rebecca Rosen
 Director of Marketing
 +1 213-213-3622
 Email Contact

Add Comment / Rating

Posted: 4 month(s) and 2 days(s) ago   |   0 Comment(s)   |   Rating: 0 0
Posted by: In_The_News

OTTAWA--(Marketwire - 11/19/09) - Wind Works Power Corp. (OTC.BB:WWPW - News) (Frankfurt:R5E1 - News) (WKN: AOKE72) is pleased to announce that it is submitting an application for its 10 megawatt (MW) Clean Breeze wind energy project for a power contract under the new Feed-in Tariff program as part of the Ontario Power Authority initial launch period.

"We are excited to be submitting our first application for a power contract under the new Feed-in Tariff program in Ontario. We expect to submit a number of additional applications for other projects in our portfolio over the coming days as we approach the November 30th deadline," commented Dr. Ingo Stuckmann, CEO and director of Wind Works. "The granting of a power contract is a big milestone as it provides economic certainty and significantly increases the value and marketability of a project."

The Feed-in Tariff (FIT) contract program is part of the new Green Energy Act in Ontario and offers a power contract with a guaranteed rate of C$135.00/MWh over a 20-year term to qualified wind energy projects. The Ontario Power Authority (OPA) initial launch period deadline for FIT applications is November 30, 2009. This first launch period is designed for projects that were being developed under the Renewable Energy retired Renewable Energy Standard Offer Program (RESOP program) and are therefore further advanced. Criteria of earlier commercial operation dates is one such factor in obtaining priority access to transmission availability. To be awarded a Power Purchase Agreement (PPA) under the FIT rules, the application has to be submitted in accordance with strict regulations which can be accessed in details via the OPA website at www.powerauthority.on.ca/

Clean Breeze is 10MW project located in Ontario, Canada in the Northumberland Hills. This project has been under development for over 3 years and is only 5kms from the north shore of Lake Ontario in an area of high elevation that can optimize the wind resources to a maximum. Annual mean wind speeds are measured at over 6.7 meters per second at an 80 m hub height.

About Wind Works:
Wind Works' mission is to become a leading developer of wind energy projects in North America and Europe. For more information, please visit: www.windworkspower.com

About Zero Emission People:
The vision of Zero Emission People is to provide the opportunity for anyone to invest early in the development of renewable wind energy projects. As an example, as little as a $10,000 investment in a wind park blows away a person's carbon footprint. We believe in making sound, environmentally conscious investments that are good for all shareholders, people and our planet.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained herein which are not historical are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements including, but not limited to, certain delays beyond the company's control, inability to successfully conclude negotiations currently in progress, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.

Wind Works Power Corp.
Investor Relations
1-877-301-9748
http://www.windworkspower.com

Add Comment / Rating

Posted: 4 month(s) and 2 days(s) ago   |   1 Comment(s)   |   Rating: 0 0
Posted by: In_The_News

Earlier this week the Chilean Institute of Public Health (ISP; http://www.ispch.cl) issued the Registration Certificate for Mellow Hope's H1N1 Influenza A Vaccine (Virion Split) The government tenders the bid in the scope of 4 to 6 million doses and had already secured the first order of 200,000 doses. This vaccine, worth approximately $1.8 million USD, will ship to the Chilean private market

HTDS' CEO Terry Yuan said "The Government of Chile showed a great agility in the fight against the H1N1. The Government does everything in its power to assure the safety of Chilean citizens and the vaccine negotiations had been exemplary ones." Mr. Yuan said further "Yes, the first 200,000 doses had been scheduled, but the final number tendered by the government is somewhere between 4 to 6 million doses. The final figures still need be worked out with the Chilean health authorities, but this is a tremendous start to our South American Expansion and we are looking forward to work with other governments in this region."

Hard to Treat Diseases (HTDS) operates two medical subsidiaries in Europe and Mainland China. HTDS is a parent company with operations in East European Serbia based pharmaceutical company Slavica Bio Chem Co and in China Mellow Hope Inc.

To receive future updates via email, including quarterly newsletters and company updates that may not be newsworthy, however important to the reader and followers of the company, please sign up today free at www.minamargroup.com/updates.

Safe Harbor Statement:
Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases Inc. that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be", "expects", "may affect", "believed", "estimate", "project" and similar words and phrases are intended to identify such forward-looking statements. Hard to Treat Diseases Inc. cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases Inc. is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases Inc.'s control. In addition to those discussed in Hard to Treat Diseases Inc.'s press releases, public filings, and statements by Hard to Treat Diseases Inc.'s management, including, but not limited to, Hard to Treat Diseases Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases Inc.'s ability to raise additional capital to fund future operations, Hard to Treat Diseases Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hard to Treat Diseases Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For any investor relations matters, please contact www.minamargroup.net/helpdesk; Investor Relations Department Inquiry, www.minamargroup.net (IR); For (M&A) and Corporate Matters, www.minamargroup.com

Add Comment / Rating

Posted: 4 month(s) and 2 days(s) ago   |   1 Comment(s)   |   Rating: 0 0
Posted by: In_The_News

AUSTIN, TX--(Marketwire - 11/19/09) - Applied Nanotech Holdings, Inc. (OTC.BB:APNT - News) announced that it has successfully inkjet printed its nanoparticle copper inks onto commercially available paper substrates forming highly conductive patterns for electronic circuits. This significant technological achievement paves the way for low cost solutions for applications such as smart labels, RFIDs, paper displays, electronic paper, and disposable electronics on paper substrates.

At the ID TechEx Printed Electronics Conference in San Jose, CA from December 1-4, 2009, Applied Nanotech will also show its latest development in Ni nanoparticle inks and nanoparticle based aluminum and copper pastes for photovoltaics and other applications. This is the largest conference in North America dedicated to the printed electronics industry, and showcases recent advances in the industry. (http://www.idtechex.com/printedelectronicsusa09/en/)

"This achievement demonstrates our ability to understand the specific needs of the industry and to use our expertise in nanotechnology to provide total solutions to our customers," said Dr. Zvi Yaniv, CEO of Applied Nanotech, Inc. "Our expertise in nanoparticles, ink formulations, printing equipment, and substrates allow us to quickly bring new technologies to market."

"We continue to broaden our portfolio of ink technologies to address application specific needs of the printed electronics industry," said Doug Baker, CEO of Applied Nanotech Holdings, Inc. "We are on the forefront of nanoparticle ink technologies and will continue to develop innovative solutions for our customers."

For more information about sales of our inks, related products, or to discuss application needs, please contact Applied Nanotech, Inc. at sales@appliednanotech.net or visit with ANI at Printed Electronics USA 2009 in San Jose, CA December 1-4.

ABOUT APPLIED NANOTECH HOLDINGS, INC.:
Applied Nanotech Holdings, Inc. is a premier research and commercialization organization focused on solving problems at the molecular level. Its team of PhD level scientists and engineers work with companies and other organizations to solve technical impasses and create innovations that will create a competitive advantage. The business model is to license patents and technology to partners that will manufacture and distribute products using the technology. Applied Nanotech has over 250 patents or patents pending. Applied Nanotech's website is www.appliednanotech.net.

SAFE HARBOR STATEMENT:
This press release contains forward-looking statements that involve risks and uncertainties concerning our business, products, and financial results. Actual results may differ materially from the results predicted. More information about potential risk factors that could affect our business, products, and financial results are included in our annual report on Form 10-K for the fiscal year ended December 31, 2008, and in reports subsequently filed by us with the Securities and Exchange Commission ("SEC"). All documents are available through the SEC's Electronic Data Gathering Analysis and Retrieval System (EDGAR) at www.sec.gov or from our website listed above. We hereby disclaim any obligation to publicly update the information provided above, including forward-looking statements, to reflect subsequent events or circumstances.

COMPANY CONTACT
Doug Baker
Applied Nanotech Holdings, Inc.
248.391.0612

Add Comment / Rating

Posted: 4 month(s) and 2 days(s) ago   |   0 Comment(s)   |   Rating: 0 0
Posted by: In_The_News

BELGRADE, Serbia, Nov. 18 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS.PK) www.htdsmedical.com Slavica Bio Chem operating subsidiary www.slavicabiochem.com is pleased to report that IBISS research group passed to the top final for biological science out of more than hundred competitors in the contest for the annual Award "Best technological innovation in Serbia in the year 2009" announced by Serbian Ministry of Science and Technological Development (MSTD).

Prof. Dr. Mirjana Stojiljkovic, a Medical Advisor of HTDS, the project and team leader of the IBISS group, said: "We are proud our idea and the marketing plan were well accepted and we hope that we shall be as successful as our colleagues from MindUp group. Namely, in the competition for the Best Technological Innovation in Serbia in the year 2008, Ministry of Science and Technological Development (MSTD) of Republic of Serbia awarded MindUp cancer project the second place in the field of biology for the establishment of the resistant human lung cancer cell line, and their contribution to overcome of multi-drug resistance, a major obstacle in the failure of standard chemotherapy". At the company website http://www.htdsmedical.com/awards.html and on http://www.pinksheets.com/pink/quote/quote.jsp?symbol=htds one can find the Certificate of this prestigious award, which was presented to the MindUp project leaders (the project was listed as 143009 in the MSTD).

Prof. Dr. Mirjana Stojiljkovic added: "Decision of the Award Committee for 2009 is expected shortly and we are hoping for the best." Additional details and information will be released promptly, via regular news release or Pink Sheets filing service.

To receive future updates via email, including quarterly newsletters and company updates that may not be newsworthy, however important to the reader and followers of the company, please sign up today free at www.minamargroup.com/updates

Safe Harbor Statement:
Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases Inc. that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be", "expects", "may affect", "believed", "estimate", "project" and similar words and phrases are intended to identify such forward-looking statements. Hard to Treat Diseases Inc. cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases Inc. is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases Inc.'s control. In addition to those discussed in Hard to Treat Diseases Inc.'s press releases, public filings, and statements by Hard to Treat Diseases Inc.'s management, including, but not limited to, Hard to Treat Diseases Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases Inc.'s ability to raise additional capital to fund future operations, Hard to Treat Diseases Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hard to Treat Diseases Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

Add Comment / Rating